April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Outcome of Macular Toxoplasmosis Following Treatment
Author Affiliations & Notes
  • Mahmoud O Jaroudi
    Ophthalmology, The Eye Center, Riyadh, Saudi Arabia
  • Khalid F Tabbara
    Ophthalmology, The Eye Center, Riyadh, Saudi Arabia
  • Samir S Shoughy
    Ophthalmology, The Eye Center, Riyadh, Saudi Arabia
  • Charbel Bou Chacra
    Ophthalmology, The Eye Center, Riyadh, Saudi Arabia
  • Footnotes
    Commercial Relationships Mahmoud Jaroudi, None; Khalid Tabbara, None; Samir Shoughy, None; Charbel Bou Chacra, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5281. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mahmoud O Jaroudi, Khalid F Tabbara, Samir S Shoughy, Charbel Bou Chacra; Outcome of Macular Toxoplasmosis Following Treatment. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5281.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To assess the structural and functional outcome of macular toxoplasmosis in a cohort of immunocompetent patients following treatment with antimicrobial agents and steroids.

 
Methods
 

Retrospective chart review of twelve patients presenting between 2007 and 2012 with ocular toxoplasmosis affecting or involving the macula (anatomic fovea centralis) was done. All patients underwent complete eye examination and received systemic antimicrobial therapy in combination with corticosteroids. Structural and functional response to treatment was assessed over the course of 10 months and documented by Snellen visual acuity test, fundus photos and optical coherence tomography images.

 
Results
 

There were four female and eight male patients with a mean age of 34 years (range, 16-54 years). The mean follow-up period after treatment initiation was 10 months (range, 8-12months). All twelve patients showed clinical evidence of improvement in visual acuity and healing of the macular retinochoroiditis within the first 4 weeks of therapy and at 6 months follow-up. Nine patients (75%) had 20/40 visual acuity or better at 6 months follow-up. Ten patients (83%) had a residual macular scar affecting their final vision. However, two patients (12%) who received treatment within the first 12-24 hours of symptoms onset had full resolution of the disease without residual macular scarring and regained 20/20 and 20/18 vision.

 
Conclusions
 

Patients with macular toxoplasmosis present earlier than patients with peripheral lesions. Early diagnosis and prompt treatment within the first 12-24 hours of symptoms onset may carry a positive prognostic value. Full resolution of macular toxoplasmic retinochoroiditis without residual scarring and restoration of 20/20 vision can be achieved in patients who are treated early with antimicrobials and steroids.

 
 
Figure: Fundus photo and OCT showing foveal toxoplasmic lesion with serous macular detachment before treatment (A, B).Fundus photo and OCT after treatment showing full resolution of retinochoroiditis and macular edema without residual scarring (C, D).
 
Figure: Fundus photo and OCT showing foveal toxoplasmic lesion with serous macular detachment before treatment (A, B).Fundus photo and OCT after treatment showing full resolution of retinochoroiditis and macular edema without residual scarring (C, D).
 
 
Table.Twelve patients with macular toxoplasmosis before and after treatment
 
Table.Twelve patients with macular toxoplasmosis before and after treatment
 
Keywords: 734 toxoplasmosis • 704 retinochoroiditis  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×